Recombinant SARS-CoV-2 S1 Subunit Protein RBD, L452Q/F490S mutant

Recombinant SARS-CoV-2 S1 subunit protein RBD, mutant L452Q/F490S with C-terminal His-tag, derived from the transfected human HEK293 cells.
As low as $313.00
In stock
Only %1 left
Catalog #:
230-30202
-
+

Product Description

Specifications

Size 100 ug, 500 ug, 1000 ug
Species SARS-CoV-2
Accession Number QHD43416
Gene Symbols S
Protein Name / Synonyms Spike protein, S Protein, S1 Subunit, Host Cell Receptor Binding Domain (RBD)
Expressed Region Arg319-Phe541. L452Q/F490S mutant: amino acid Leu (L) at 452 position was mutated to Gln (Q), Phe (F) at 490 position was mutated to Ser (S).
Expression System HEK293 cells
Tag C-terminal his-tag
Purification His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Purity >95%
Purity Determined By SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Molecular Weight (kDa) Recombinant protein product has a calculated molecular mass of ∼25 kDa. Due to the abundant glycosylation, it migrates as approximately ∼30 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. After deglycosylation under native and denature conditions, the protein presented as one reduced ∼25 kDa band.
Format Liquid
Formulation Supplied as a 0.2 µm filtered solution in PBS (pH 7.4)
Concentration (lot specific) Lot specific (see the label on the vial), determined by BCA protein assay
Specificity SARS-CoV-2 Lambda Variant C.37 (Peru)
Endotoxin Level < 0.5 EU per µg of the protein as determined by the LAL method
Estimated Lead Time 2-3 weeks
Shipping Type Blue ice
Storage -20°C
SDS-PAGE Image
SDS-PAGE
Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.
Lane 1: Protein standard ladder (kDa).
Lane 2: Untreated protein
Lane 3: Treated protein with deglycosylation enzymes under native conditions.
Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.
Binding Function
Binding Function
Product binding ability was measured by ELISA. The immobilized recombinant human ACE2 protein (Catalog #230-30165, coated at 0.5 µg/ml, 100 µl/well) was incubated with the serial diluted SARS CoV-2 S1 RBD L452Q/F490S mutant protein (Catalog #230-30202). The bound mutant protein was detected by mouse anti-S1 RBD monoclonal antibody using ELISA. The calculated EC50 is 21.57 ng/ml.

Stability & Storage

Shipping
Ice packs
Storage/Stability
Upon arrival, the protein may be stored for 2 weeks at 4 °C. For long term storage, it is recommended to store at -20 °C or -80 °C in appropriate aliquots. Avoid repeated freeze-thaw cycles.

Custom Labeling Request

We can custom label this protein with biotin or fluorescent dyes (choose from violet, blue, green or red). Request now.
Write Your Own Review
Your Rating
Submit a review for this product on Biocompare.com to earn an entry into a monthly raffle for one of five $100 Amazon gift cards!

Ask a Question

Display name:
Your location:*
This field is for validation purposes and should be left unchanged.